EGFR and colorectal cancer: However, a lot of papers revealed the efficacy of anti-EGFR plus chemotherapy treatment for patients with CRLMs, and four RCT studies have already been published before 2011 [9–12], and even a meta-analysis has been published in 2012 [13] showing a higher level of evidence-based medical evidence on the benefit and disadvantages using anti-EGFR agents in combination with chemotherapy treatment for patients with colorectal cancer, but there are still some controversial issues such as whether cetuximab increases overall survival (OS) or not.